Overview: HLA-DPA1 DPB1 Typing TestIntroduction: The HLA-DPA1 DPB1 Typing Test types HLA-DPA1 and DPB1 antigens to assess transplant compatibility, preventing rejection. Aligned with 2023 ASHI guidelines, it uses PCR for high specificity, supporting transplant screening. This test is critical for guiding transplant decisions, matching donors, and improving outcomes in molecular pathology for patients undergoing organ or bone marrow transplantation.
Other Names: HLA-DPA1 & DPB1 Assay, HLA Class II Typing Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: HLA typing began in the 1960s with transplant immunology. PCR-based HLA-DPA1 and DPB1 typing improved in the 2000s, enhancing compatibility assessment.
Purpose: Assesses HLA-DPA1 and DPB1 for transplant compatibility, guides donor matching, and prevents rejection in patients.
Test Parameters: 1. HLA-DPA1 & DPB1 Antigens
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva at any time. Report history of transplants, autoimmune diseases, or family history of HLA-related conditions.
Specimen: 2-5 mL whole blood (EDTA), 1-2 buccal swabs (sterile swab), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document history of transplants, autoimmune diseases, or family history of HLA-related conditions. Include current medications and prior transplant history.
Consent: Written consent required, detailing the tests purpose, compatibility implications, and potential need for transplant planning.
Procedural Considerations: Uses PCR to type HLA-DPA1 and DPB1 antigens. Results are available in 3-5 days, enabling clinical decisions. Performed in laboratories, often for transplant compatibility.
Factors Affecting Result Accuracy: Improper sample handling or contamination can affect results. Low DNA quality may impact typing accuracy.
Clinical Significance: HLA-DPA1 and DPB1 typing ensures donor-recipient compatibility, reducing rejection risk. Mismatches guide immunosuppression planning.
Specialist Consultation: Consult a transplant immunologist or hematologist for result interpretation and transplant planning.
Additional Supporting Tests: HLA-A, HLA-B typing, or antibody screening to assess transplant compatibility.
Test Limitations: Limited to HLA-DPA1 and DPB1; other loci may need testing. Clinical correlation is needed.
References: ASHI HLA Guidelines, 2023; Human Immunology, Tait BD, 2022.
